|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Non-cash consideration for acquired in-process research and development | |||||
| Change in fair value of Sermonix pre-funded warrant | |||||
| Stock-based compensation | |||||
| Depreciation expense | |||||
| Non-cash lease expense | |||||
| Amortization of premiums and accretion of discounts on available-for-sale securities, net | |||||
| Loss on disposal of equipment | |||||
| Changes in operating assets and liabilities: | |||||
| Unbilled grant receivable | |||||
| Prepaid expenses and other current and long-term assets, net | |||||
| Insurance recovery receivable related to legal settlement | |||||
| Accounts payable and accrued liabilities | |||||
| Accrued legal settlement | |||||
| Operating lease liability | |||||
| Other long-term liabilities | |||||
| Net cash used in operating activities | |||||
| Investing activities | |||||
| Purchases of available-for-sale securities | |||||
| Maturities of available-for-sale securities | |||||
| Purchases of property and equipment | |||||
| Net cash (used in) provided by investing activities | |||||
| Financing activities | |||||
| Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan. | |||||
| Proceeds from PIPE financing | |||||
| Issuance costs from PIPE financing | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash, beginning of period | |||||
| Cash, cash equivalents and restricted cash, end of period | |||||
Loading...
